AGM
GALT icon

Alpine Global Management’s Galectin Therapeutics GALT Stock Holding History

Alpine Global Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,555
Closed -$44.2K – 264
2024
Q2 		$44.2K Buy
+19,555
New +$59.4K 0.01% 445
2019
Q2 		– Sell
-19,093
Closed -$98K – 81
2019
Q1 		$98K Sell
19,093
-4,258
-18% -$20.4K 0.03% 86
2018
Q4 		$80K Buy
+23,351
New +$112K 0.02% 215
2015
Q3 		– Sell
-13,681
Closed -$37K – 372
2015
Q2 		$37K Buy
+13,681
New +$41.2K 0.01% 844

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Alpine Global Management's GALT Position: Q3 2024 in Review

Alpine Global Management sold out of Galectin Therapeutics (GALT) in Q3 2024, closing a stake of 19,555 shares — an estimated $44.2K sold.

Alpine Global Management first reported a position in GALT in Q2 2015 and held it in 4 quarters. The position peaked at $98K in Q1 2019. 79 funds tracked by Wall St. Rank hold GALT as of Q3 2024.

  • Alpine Global Management reported no remaining Galectin Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 19,555 Galectin Therapeutics shares in Q3 2024, an estimated $44.2K.
  • Alpine Global Management first reported a position in Galectin Therapeutics in Q2 2015 and held it in 4 quarters.
  • Alpine Global Management's Galectin Therapeutics position peaked at $98K in Q1 2019.
  • 79 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.